Rachelle Jacques, Enzyvant CEO
An FDA mistake signals likely approval for first therapy for children born without a thymus
The FDA on Thursday accidentally published a notice announcing the award of a priority review voucher to rare disease drug developer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
